Dr. Moasser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1825 fourth street
San Francisco, CA 94158Phone+1 415-353-7070Fax+1 415-353-7021
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1996
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1988 - 1991
Tufts University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2004 - 2025
NY State Medical License 1989 - 2005- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Feb 01
- Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 Start of enrollment: 2007 Aug 01
- Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27
Publications & Presentations
PubMed
- 745 citationsEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.Natalia Sergina, Megan Rausch, Donghui Wang, Jimmy A. Blair, Byron Hann
Nature. 2007-01-25 - 278 citationsA phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerPamela N. Munster, K. T. Thurn, Scott Thomas, Paromita Raha, Mira Lacevic
British Journal of Cancer. 2011-06-07 - 770 citationsThe oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesisMark M. Moasser
Oncogene. 2007-10-04
Press Mentions
Trial Confirms That Perjeta Extends Survival in Metastatic Breast CancerSeptember 28th, 2014
Solving the Mystery of a Stubborn, and Common, Cancer GeneMarch 5th, 2022
Grant Support
- Understanding Resistance To HER Family Tyrosine Kinase InhibitorsNational Cancer Institute2007–2011
- Adhesion Signaling By A Novel Mitotic Substrate Of SRCNational Cancer Institute2005–2009
- Pilot Studies To Develop Probes For In Vivo Imaging Of P13k/Akt Pathway ActivityNational Cancer Institute2007–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
